The World Health Organization (WHO) Global TB Program launched a call for submissions of best practices on the engagement of affected communities and civil society to accelerate progress to end TB.

The World Health Organization releases the first-ever report on the pipeline of the vaccines currently in development to prevent infections caused by antimicrobial-resistant bacterial pathogens.

The use of nanopore sequencing for the early identification of pulmonary tuberculosis (TB) infection had superior diagnostic accuracy compared with both Mycobacterium tuberculosis (MTB) culture analyses and Xpert MTB/rifampin (RIF) assays, according to results of a study published in International Journal of Infectious Diseases.

The goal to eliminate TB by 2030 can happen if lessons learned from COVID are implemented. This includes investing in health and telemedicine.

The studies followed up 4,022 TB patients and 12,243 gender-matched and age-matched controls for their long term survival. Even though TB patients were treated successfully, the long-term follow-up of individuals treated for TB showed that there was an excess of premature deaths among those affected by the disease, the key findings stated.

The World Health Organization releases updated guidelines and a new operational handbook on TB care and support to improve the quality of life and better outcomes for people with TB.

Minister of Health Mam Bun Heng has instructed health officials at provincial and district hospitals, as well as health centres, to diagnose tuberculosis (TB) as early as possible, particularly in malnourished children, children living with HIV and AIDS, and children with severe pneumonia.

On February 24, 2022, the Centers for Disease Control and Prevention (CDC) published new interim guidance in Morbidity and Mortality Weekly Report on a 4-month treatment regimen as an option for US patients with drug-susceptible pulmonary tuberculosis (TB).[1] The 4-month treatment regimen consists of high-dose daily rifapentine with moxifloxacin, isoniazid, and pyrazinamide. Shorter regimens help patients complete treatment faster.

ICMR's top tuberculosis research institute NIRT is in the process of developing and validating sputum-free tests using blood, stool, urine and saliva samples for diagnosing the disease.

-- Some of the new tools introduced include eight ultra-portable digital chest X-ray machines that are battery-operated.

-- The machines emit lower doses of radiation and can be packed into backpacks and so easily transported into the field.